Organon & Co.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Organon & Co.
Sanjiv Navangul, managing director and CEO, Bharat Serums and Vaccines, in a wide-ranging interview with Scrip, outlines the firm’s game plan to establish itself as a “force to reckon with” in women’s health - it goes beyond drugs and encompasses devices and potentially digital therapeutics as well. The former Janssen India chief also weighs in on the worrying industry-wide input cost escalation scenario and supply chain turbulence.
A post-pandemic rebound in oncology sales contrasts with the lagging revenues of drugs administered by primary care and office-based specialists. Declining COVID-19 vaccine, diagnostic and treatment revenues could add further volatility.
Rising Leader Therese Liechtenstein is playing an integral part in the creation and financing of multiple companies in the M Ventures portfolio, guiding them towards key value inflection points that a potential partner or acquirer would like to see.
Organon commercial director and lead for the South Asia Region, Anjan Sen, lays out how the Merck spin-out expects to scale up activities in markets like India. A mix of new products, targeted repurposing efforts and access-driven pricing are part of the strategy that could potentially see the company double its presence in the region.
- Other Names / Subsidiaries
- Alydia Health
- Forendo Pharma Oy
- Organon NV
- Organon & Co.